Notice: Oncosil™ is currently approved in the following jurisdictions:
Transforming the prognosis
BREAKTHROUGH LOCALLY ADVANCED PANCREATIC CANCER TREATMENT
OncoSil Medical is a Sydney based medical device company focused on Interventional Oncology. OncoSil Medical’s lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient’s pancreatic tumour via endoscopic ultrasound. OncoSil™ was granted CE Marking for locally advanced pancreatic cancer in combination with standard of care chemotherapy. The device is designated as a breakthrough device in the European Union, United Kingdom and the United States.